Brean Murray Carret & Co. Upgrades Onyx Pharmaceuticals (ONXX) to Buy; Misleading Documents...FDA Approval Is Coming
Tweet Send to a Friend
Brean Murray Carret & Co. upgraded Onyx Pharmaceuticals (NASDAQ: ONXX) from Hold to Buy with a price target of $60.00.
This article: 182 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This article: 182 words
-->
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
